Orders exceeded $1 billion and revenue grew 5% year-over-year in Q2 2026, with strong demand in Protein Solutions and robust cash flow. Adjusted EBITDA margin improved to 17.1%, and full-year guidance for revenue and margins was reiterated despite a $33 million impairment charge.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.